Lyell Immunopharma (LYEL) Other Non-Current Liabilities (2020 - 2026)

Lyell Immunopharma has reported Other Non-Current Liabilities for 7 years, with the latest figure at $527000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 83.22% year-over-year to $527000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $527000.0 (down 83.22% YoY) and the FY2025 annual result came in at $517000.0, down 84.11% from the prior year.
• Other Non-Current Liabilities rose to $527000.0 in Q1 2026 per LYEL's latest filing, from $517000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.5 million in Q2 2025 and troughed at $517000.0 in Q4 2025.
• A 5-year average of $3.5 million and a median of $3.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities soared 382.22% in 2022, then slumped 84.11% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $4.1 million in 2022, then dropped by 10.92% to $3.7 million in 2023, then dropped by 11.22% to $3.3 million in 2024, then plunged by 84.11% to $517000.0 in 2025, then increased by 1.93% to $527000.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $527000.0, $517000.0, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.